Baxter International Inc

Most Recent

  • uploads///Q EPS
    Earnings Report

    Weighing in with Boston Scientific’s 4Q15 Revenues

    Boston Scientific reported its 4Q15 earnings on February 4 and registered adjusted EPS of $0.26 in 4Q15, which represents 18% YoY growth.

    By Sarah Collins
  • uploads///projections
    Earnings Report

    Becton, Dickinson and Company’s 4Q16 Earnings Estimates

    Wall Street projected a rise in Becton, Dickinson and Company’s (BDX) adjusted net profit margins. The margins are expected to come in at ~$453 million.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results

    On January 29, 2018, Abbott Laboratories (ABT) closed trading at $63.31 per share. The company reported its 52-week high of $64.60 on January 25.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Inside Abiomed’s Profit Margin Expectations for Fiscal 2018

    For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.

    By Margaret Patrick
  • uploads///core strategies
    Company & Industry Overviews

    How Are Stryker’s Core Strategies Working Toward Its Growth?

    Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

    By Sarah Collins
  • uploads///stock price
    Company & Industry Overviews

    Abbott Laboratories’ Stock Performance after a Recent Bull Run

    On February 16, Abbott Laboratories (ABT) closed trading at $60.17 per share.

    By Sarah Collins
  • uploads///US Investment Grade Bond Fund Flows
    Company & Industry Overviews

    Investment-Grade Bond Funds Saw Outflows Last Week

    Flows into investment-grade bond funds (LQD) were negative in the week ending June 17. This was the second consecutive week witnessing outflows.

    By David Ashworth
  • uploads///SP  index
    Company & Industry Overviews

    S&P 500 Index Nears Record High amid Earnings Season

    The S&P 500 Index, represented by the SPDR S&P 500 ETF (SPY), rose 0.3% on October 23, nearing the all-time high it saw in July.

    By Maitali Ramkumar
  • uploads///revenue estimates
    Earnings Report

    Baxter Exhibits Strong 1Q16 Performance, Beat Estimates

    On April 26, 2016, Baxter International (BAX) released its 1Q16 earnings. After the announcement, Baxter’s share price rose ~1% from $43.63 on April 25, 2016, due to the company’s better-than-expected 1Q16 results.

    By Sarah Collins
  • uploads///COMPLEMENTARY PORTFOLIO
    Company & Industry Overviews

    Effect of Claris Injectables Acquisition on Baxter’s 2017 Growth

    On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.

    By Sarah Collins
  • uploads///US Investment Grade Bond Market Issuance
    Company & Industry Overviews

    Issuance of Investment-Grade Corporate Bonds Fell Last Week

    Baxalta, Energy Transfer Partners, JPMorgan Chase, Occidental Petroleum, and Cardinal Health were among the biggest issuers of investment-grade corporate bonds last week.

    By David Ashworth
  • uploads///Grph
    Company & Industry Overviews

    Can Edwards Lifesciences See Robust Net Profit Margin in 2017?

    In its 2Q17 earnings conference call, Edwards Lifesciences (EW) projected 2017 adjusted EPS to fall to $3.65–$3.85, which is higher than the previous $3.43–$3.55.

    By Margaret Patrick
  • uploads///Part
    Consumer

    Dan Loeb’s Third Point Looks to Baxter and Campbell Soup in 2019

    During Q4 2018, Third Point reduced its stake by ~33% in healthcare company Baxter International (BAX).

    By Anuradha Garg
  • uploads///Part
    Materials

    Dan Loeb Increased Third Point’s Position in These Stocks in Q4

    In Q4 2018, Third Point initiated a new position in Cigna (CI), which is an American healthcare services organization.

    By Anuradha Garg
  • uploads///Graph
    Company & Industry Overviews

    What Are Abbott Laboratories’ Key Growth Drivers in 2019?

    On its fourth-quarter earnings call, Abbott forecast that its Established Pharmaceuticals segment would grow in the mid- to high single digits YoY in the first quarter.

    By Margaret Patrick
  • uploads///Chart  Healthcare
    Company & Industry Overviews

    GE’s Healthcare Unit Spin-Off to Enhance Shareholder Wealth

    As part of its June 2018 major restructuring plan, General Electric (GE) intends to spin off the Healthcare segment and turn it into a standalone entity.

    By Anirudha Bhagat
  • uploads///checklist _
    Company & Industry Overviews

    Baxter International: Why Investors Are Interested

    Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///SYk ana reco
    Earnings Report

    What Analysts Recommend for Stryker Stock

    Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.

    By Kenneth Smith
  • uploads///STOCK PRICE
    Company & Industry Overviews

    ABT Stock Registered a 52-Week High in October

    On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close.

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Abbott Laboratories Stock Trades at Its 52-Week High in September

    On September 18, Abbott Laboratories (ABT) ended the trading day at $68.41, up ~1.1% from its previous trading day’s closing price.

    By Sarah Collins
  • uploads///BAX
    Company & Industry Overviews

    Baxter’s Global Business Units Continue to Deliver

    Baxter International’s (BAX) global business units delivered strong performances in the second quarter.

    By Kenneth Smith
  • uploads///checklist _
    Earnings Report

    How Baxter International Fared in the Second Quarter

    Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.

    By Kenneth Smith
  • uploads///hospital _
    Company & Industry Overviews

    How Wall Street Analysts View TransEnterix

    Of the five analysts tracking TransEnterix in July, two of them have recommended a “strong buy,” and one has recommended a “buy.”

    By Daniel Collins
  • uploads///health _
    Company & Industry Overviews

    Analyst Recommendations for Boston Scientific and Peers in June

    Of the 24 analysts covering Boston Scientific in June, 19 of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///computer _
    Company & Industry Overviews

    How Much Upside Do Analysts See in Baxter Stock?

    Of the 17 analysts covering Baxter International in June, ten of them have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///BAX
    Company & Industry Overviews

    A Close Look at Baxter International’s Acquisitions

    Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    BAX May See Slight Rise in Net Profit Margins in Fiscal 2018

    In 4Q17, Baxter International (BAX) reported adjusted earnings per share close to $0.64, which represents year-over-year growth of 12.0%.

    By Margaret Patrick
  • uploads///daniel frank  unsplash
    Company & Industry Overviews

    Analysts’ March 2018 Ratings for Baxter International and Peers

    In March, 17 analysts tracked Baxter International. Three gave a “strong buy” rating, seven gave a “buy” rating, and six suggested a “hold.”

    By Margaret Patrick
  • uploads///baxter
    Company & Industry Overviews

    Baxter International Completes Its Mallinckrodt Assets Buy

    Baxter (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt for $185.0 million.

    By Sarah Collins
  • uploads///ABMD RD
    Company & Industry Overviews

    Why Abiomed’s Product Pipeline Looks Promising

    Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps.

    By Kenneth Smith
  • uploads///DEAL RATIONALE
    Company & Industry Overviews

    Rationale behind Varian Medical’s Acquisition of Sirtex Medical

    On January 30, 2018, Varian Medical Systems (VAR) announced that it had entered into an agreement to acquire Sirtex Medical Limited for $1.3 billion.

    By Sarah Collins
  • uploads///RECMMENDATIONS
    Company & Industry Overviews

    Wall Street Issues Majority ‘Buy’ Ratings on Align Technology

    On December 29, 2017, according to 12 investment brokerage firms which were part of a Reuters survey, Align Technology stock has received a “buy” rating from 11 analysts.

    By Sarah Collins
  • uploads///q guidance
    Company & Industry Overviews

    Baxter International Expected to Post Strong 4Q17 Results

    Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]

    By Sarah Collins
  • uploads///free cash flow
    Company & Industry Overviews

    What’s Driving Baxter International’s Cash Flow Growth

    Baxter International’s 2017 cash flow Between 9M16 (the first nine months of 2016) and 9M17, Baxter International’s (BAX) cash flow rose by $514 million to $933 million, exceeding its cash flow of $905 million in fiscal 2016. In fiscal 9M17, Baxter had operating cash flow of ~$1.3 billion, up $405 million from fiscal 9M16. In fiscal 2017, Baxter expects to […]

    By Sarah Collins
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Discussing Baxter International’s Recent Stock Price Highs

    On January 4, 2018, Baxter International was trading at a 52-week high of $68.86 per share, ending the day at $68.41 per share.

    By Sarah Collins
  • uploads///EMERGING MARKET PERFORMANCE
    Company & Industry Overviews

    How Emerging Markets Continue to be the Key Growth Driver for BD

    Overview BD (BDX) has significantly diversified operations around the world. It has a diverse base in emerging markets such as Eastern Europe, Latin America, Africa, the Middle East, and certain Asia-Pacific countries. The company is focused on expanding its operations in these high-growth markets and is undertaking strategic initiatives in this regard. It is mainly focused […]

    By Sarah Collins
  • uploads///guidance
    Company & Industry Overviews

    Baxter International’s Latest Guidance for Fiscal 2017

    Baxter International’s sales growth guidance for fiscal 2017 is expected to be ~4% on a reported basis.

    By Sarah Collins
  • uploads///intralipid iv emulsion
    Earnings Report

    Chart in Focus: Baxter International’s Intralipid 20% Recall

    On October 5, 2017, Baxter International (BAX) announced the voluntary recall of a shipment from a lot of Intralipid 20% IV Fat Emulsion, 100 mL. This lot was distributed from August 11 to August 31, 2017.

    By Sarah Collins
  • uploads///operational efficiency
    Company & Industry Overviews

    Management Changes at Baxter International: What You Should Know

    Baxter International (BAX) has been going through a cost transformation and reorganization process for some time. The initiative includes some leadership and management changes.

    By Sarah Collins
  • uploads///EPS ESTIMATES
    Company & Industry Overviews

    Inside Baxter International’s Stock Price Performance

    On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    EMEA and APAC: Fresenius Medical Care’s Dialysis Products Business

    In 1H17, Fresenius Medical Care (FMS) earned ~1.6 billion euros from the sale of dialysis products, which equals year-over-year growth of 8% on a reported basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Abiomed Expects to Expand Its Presence in This Space

    Abiomed is primarily focused on the growth opportunity in the protected PCI area, a procedure that is applicable for patients with coronary artery disease.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Abiomed in 2017: The Analysts’ View

    For the quarter ending March 31, 2017, Abiomed (ABMD) reported revenues close to $124.7 million, which represents a YoY growth of about 30%.

    By Margaret Patrick
  • uploads///stock
    Company & Industry Overviews

    Behind Thermo Fisher’s Recent Stock Performance

    TMO stock was trading at $173.2 on May 30, 2017. The stock had a 50-day moving average of $165.9 and a 200-day moving average of $153.8 that day.

    By Sarah Collins
  • uploads///CAPITAL DEPLOYMENT
    Company & Industry Overviews

    Understanding Thermo Fisher’s Capital Deployment Strategy

    Thermo Fisher Scientific expects to deploy 60%–75% of its capital toward M&As (mergers and acquisitions).

    By Sarah Collins
  • uploads///innovation
    Company & Industry Overviews

    Understanding Thermo Fisher’s Growth Strategy

    Thermo Fisher Scientific (TMO) has always focused on innovation as a key growth strategy.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    How Is Mylan’s Generics Segment Doing?

    Mylan’s (MYL) 3Q16 revenues were mainly driven by a 17.0% rise in sales for its Generics segment. The segment reported $2.6 billion in sales in 3Q16.

    By Mike Benson
  • uploads///revenues
    Company & Industry Overviews

    Analyzing Zimmer Biomet Holdings’ Financial Guidance for 2016

    Zimmer Biomet revised its 2016 guidance after reporting its 3Q16 earnings. Its guidance for fiscal 2016 is estimated to be $7.63 billion–$7.65 billion.

    By Sarah Collins
  • uploads///financial terms
    Company & Industry Overviews

    Financial Metrics of Baxter’s Acquisition of Claris Injectables

    The injectables business of Claris Lifesciences comprises 70.0%–80.0% of its total sales. Claris plans to repatriate about 85.0% of the generated funds to its shareholders.

    By Sarah Collins
  • uploads///capital allocaton
    Company & Industry Overviews

    Baxter’s Latest Dividend and Share Repurchase Authorization

    Baxter International (BAX) announced a quarterly cash dividend of $0.13 per share on November 8, 2016.

    By Sarah Collins
  • uploads///eps estimates
    Earnings Report

    Boston Scientific’s 3Q16 Earnings Beat Analysts’ Estimates

    Boston Scientific (BSX) reported its 3Q16 earnings on October 26, 2016. It registered adjusted EPS of $0.27 in 3Q16. It had ~12.5% YoY growth.

    By Sarah Collins
  • uploads///performance
    Company & Industry Overviews

    Baxter International’s Recent Product Launches and Partnerships

    Baxter International’s R&D investments were around $150 million in 2Q16, which represents a YoY (year-over-year) increase of around 1%.

    By Sarah Collins
  • uploads///bd medical
    Earnings Report

    Becton Dickinson’s BD Medical Segment Sales in Fiscal 3Q16

    Becton, Dickinson and Company, or BD (BDX), reported ~$3.2 billion in worldwide revenue in fiscal 3Q16. Of that, ~$2.2 billion was generated by BD Medical, a segment that contributed ~70% to BD’s total revenues.

    By Sarah Collins
  • uploads///innovation
    Company & Industry Overviews

    How Innovation Is Driving Thermo Fisher Scientific’s Growth

    Thermo Fisher Scientific now has more than 800,000 products in its portfolio and has an extensive product pipeline.

    By Sarah Collins
  • uploads///fin model
    Company & Industry Overviews

    Understanding Thermo Fisher Scientific’s Financial Model

    Thermo Fisher Scientific aims to deliver adjusted EPS in the range of $11.3–$12.2 by 2019. This represents a three-year CAGR of 12%–15%.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Profit Booking Leaves the iShares US Medical Devices ETF (IHI) in the Red

    On May 19, markets declined, with the SPDR S&P 500 ETF dropping by 0.3% and the iShares US Medical Devices ETF (IHI) declining by 0.8%.

    By Peter Neil
  • uploads///profitability
    Earnings Report

    Baxter’s 1Q16 Profitability and 2016 Guidance

    Baxter International (BAX) revised its 2016 guidance as the company reported a strong 1Q16. Sales guidance for the year is updated from the 2%–3% range to approximately 3%.

    By Sarah Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Inside IHI’s Large-Caps: Becton Dickinson Rose on Good 2Q16

    Becton Dickinson (BDX) announced its 2Q16 earnings on May 5, 2016. Becton Dickinson closed at $160.43 and was trading above the 20-day moving average. The stock has risen 4.1% YTD.

    By Peter Neil
  • uploads///hospital products
    Earnings Report

    Innovation Drove Baxter’s Hospital Products Sales in 1Q16

    Baxter International (BAX) reported ~$2.4 billion in total revenues in 1Q16. Of that, ~$1.5 billion was contributed by the company’s Hospital Products business.

    By Sarah Collins
  • uploads///Share price after shire baxalta deal
    Company & Industry Overviews

    The Shire-Baxalta Merger: A Look at the Details

    Following news of the Shire-Baxalta merger, Baxalta’s share price rose and Shire’s share price fell.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    IHI Large-Caps: Baxter Launches Mobile Health App in India

    In a press release, Baxter International (BAX) announced that it has launched a new mobile app in India called Sisu Janani Seva. It’s also known as mHealth.

    By Peter Neil
  • uploads///strategic initiatives
    Company & Industry Overviews

    Strategic Initiatives Driving Baxter’s Margin Expansion Goal

    Baxter witnessed a series of changes in 2015, including a change in management, operational structure, and the establishment of a new strategic framework.

    By Sarah Collins
  • uploads///services and solutions
    Company & Industry Overviews

    Why Medtronic Is Diversifying beyond Medical Devices

    Medtronic established a services and solutions growth vector as one of its core strategies. It contributed ~20 basis points to Medtronic’s growth in 3Q16.

    By Sarah Collins
  • uploads///strategic initiatives
    Company & Industry Overviews

    Baxter’s Position in Emerging Markets—and the Potential Risks

    Emerging market economies like China, Brazil, and Russia have been facing difficult conditions in 2016. Baxter has 25% of its operations in such markets.

    By Sarah Collins
  • uploads///strategic initiatives
    Company & Industry Overviews

    How Baxter’s Biosciences Spin-off into Baxalta Improved Its Valuation

    On July 1, 2015, Baxter separated its Biosciences division into a new entity named Baxalta in an effort to divest risky segments and streamline operations.

    By Sarah Collins
  • uploads///revenues
    Company & Industry Overviews

    How a Strong Product Portfolio Drives Thermo Fisher’s Valuations

    Thermo Fisher Scientific (TMO) registered sales of $4.7 billion, representing year-over-year growth of 4% in 4Q15 and fiscal 2015 sales of ~$17 billion.

    By Sarah Collins
  • uploads///geographic segmentation
    Company & Industry Overviews

    The Geographic Strategy of Thermo Fisher Scientific

    Thermo Fisher Scientific is a global company, but the majority of its revenues are generated from the developed markets. The US is its largest market, generating ~48% of the company’s total revenues.

    By Sarah Collins
  • uploads///BD Life Sciences Segment
    Earnings Report

    BD Life Sciences Sales Hit by Weak Diagnostics Segment

    In 1Q16, BD’s growth in its preanalytical and biosciences segment drove the BD Life Sciences segment sales.

    By Sarah Collins
  • uploads///laboratory producst and services
    Company & Industry Overviews

    Thermo Fisher Scientific’s Laboratory Products and Services Segment

    Thermo Fisher Scientific’s Laboratory Products and Services segment earned revenues of approximately $6.6 billion in 2014, representing organic growth of around 5%.

    By Sarah Collins
  • uploads///global footprint
    Company & Industry Overviews

    Analyzing Becton, Dickinson and Company’s Geographic Strategy

    Becton, Dickinson and Company (BDX), or BD, has operations across the globe, with more than 50% of its 2015 revenues coming from international markets.

    By Sarah Collins
  • uploads///bds history timeline
    Company & Industry Overviews

    Becton, Dickinson and Company: A Leading Global Medical Device Company

    Becton, Dickinson and Company, or BD, headquartered in Franklin Lakes, New Jersey, is one of the leading medical technology companies in the United States.

    By Sarah Collins
  • uploads///REVENUE SEGMENTS
    Company & Industry Overviews

    An Overview of Becton, Dickinson and Company’s Business Model

    On October 1, 2015, BD underwent organizational restructuring to better align its business model to the strategic vision and goals of the company.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    A Must-Read Overview of the Medical Device Industry

    The US medical device market is projected to grow at a compound annual growth rate of 6.1% between 2014 and 2017.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk’s Hemophilia and Growth Disorder Research

    In April 2015, Novo Nordisk (NVO) announced positive results from a Phase 3 clinical trial of N8-GP (turoctocog alfa pegol), a hemophilia drug.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novo Nordisk Plans to Pursue Leadership in Hemophilia Market

    Novo Nordisk is pursuing leadership in the hemophilia market with its new drugs as well as a few investigational hemophilia drugs in its late-stage research pipeline.

    By Margaret Patrick
  • uploads///Graph Part
    Company & Industry Overviews

    XLV Gained 1% as 60% of Portfolio Ended Positively for the Day

    XLV outperformed the broader market representative SPDR S&P 50 ETF on October 1, 2015. SPY rose by 0.26% , compared with XLV’s 1.01%.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    The Biotech Sector Is in a Downward Long-Term Trend

    Though most of the biotech stocks rebounded from the recent lows, the long-term trend for biotech seems to be heading downward.

    By Peter Neil
  • uploads///Article
    Company & Industry Overviews

    Understanding Leverage for Abbott Laboratories

    Abbott Laboratories (ABT) uses both equity and debt for its working capital requirements as well as investments in the business.

    By Mike Benson
  • Healthcare

    Must-know: Insurance exchanges will affect medical device stocks

    Big change to come in the healthcare industry Ready or not, state-run insurance exchanges will be ready for open enrollment starting October 1. The introduction of these public exchanges for individuals and small group employers highlights a significant change in the healthcare industry. Making consumer access to healthcare easier, more than 30 million people are […]

    By Amritpal Khalsa
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.